688399.SHG Jiangsu Bioperfectus Technologies Co Ltd
- Market cap
- CNY 2.96B
- P/E
- -
- P/B
- 0.94x
- ROE
- 0.9%
- Dividend yield
- 9.90%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 688399.SHG undervalued?
Graham numberThe Graham number of Jiangsu Bioperfectus Technologies Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Jiangsu Bioperfectus Technologies Co Ltd fundamental analysis
No fundamental analysis for Jiangsu Bioperfectus Technologies Co Ltd yet.
Jiangsu Bioperfectus Technologies Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Jiangsu Bioperfectus Technologies Co Ltd
Jiangsu Bioperfectus Technologies Co., Ltd., a molecular diagnostic company, engages in the research, development, production, and sale of in vitro diagnostic products in China. The company offers in vitro diagnostic reagents and supporting testing equipment, as well as in vitro testing services. It also provides HPV and cervical cancer testing services, respiratory infection detection solution, solutions for infectious diarrhea, and STI detection solution for reproductive t…
Full company profileJiangsu Bioperfectus Technologies Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Jiangsu Bioperfectus Technologies Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 129M | 187M | 231M | 289M | 1.74B | 2.84B | 5.53B | 403M | 350M | 340M | 305M |
| Gross Profit | 105M | 155M | 189M | 236M | 1.35B | 1.96B | 3.15B | 149M | 202M | 340M | 192M |
| Operating Income | 8.36M | 50.6M | 73.3M | 95.0M | 963M | 1.39B | 2.15B | -365M | 8.81M | -30.9M | -31.3M |
| EBITDA | 19.2M | 60.0M | 86.9M | 112M | 983M | 1.43B | 2.23B | -300M | 61.3M | 17.7M | 55.3M |
| Net Income | 8.36M | 42.7M | 63.8M | 83.8M | 820M | 1.19B | 1.83B | -374M | -2.00M | -39.7M | 25.3M |
| EPS | 0.14 | 0.66 | 0.98 | 1.25 | 9.45 | 14 | 21 | -4.31 | -0.02 | -0.47 | 0.20 |
| Balance Sheet | |||||||||||
| Total Assets | 286M | 311M | 396M | 1.15B | 2.28B | 3.50B | 4.89B | 3.91B | 3.74B | 3.55B | 3.67B |
| Total Liabilities | 34.1M | 50.4M | 71.5M | 134M | 613M | 963M | 1.11B | 501M | 489M | 626M | 724M |
| Shareholders' Equity | 252M | 260M | 324M | 1.02B | 1.66B | 2.54B | 3.78B | 3.41B | 3.25B | 2.93B | 2.94B |
| Cash & Short-term Investments | 12.4M | 21.7M | 212M | 829M | 1.44B | 1.91B | 2.81B | 2.46B | 1.95B | 484M | 303M |
| Total Debt | 186K | 151K | 65.8K | 177K | 50.0M | 164M | 104M | 166M | 235M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 22.1M | 61.6M | 85.8M | 107M | 936M | 986M | 1.96B | -113M | 146M | 30.3M | - |
| Capital Expenditure | 22.4M | 29.3M | 98.7M | 106M | 135M | 304M | 351M | 111M | 62.9M | 64.5M | 89.2M |
| Free Cash Flow | -279K | 32.3M | -12.9M | 944K | 801M | 682M | 1.61B | -224M | 83.1M | -34.1M | -121M |
| Ratios | |||||||||||
| ROE | 3.3% | 16.4% | 19.7% | 8.2% | 49.2% | 47.0% | 48.4% | -11.0% | -0.1% | -1.4% | 0.9% |
| ROA | 2.9% | 13.7% | 16.1% | 7.3% | 36.0% | 34.1% | 37.4% | -9.6% | -0.1% | -1.1% | 0.7% |
| Net Profit Margin | 6.5% | 22.8% | 27.7% | 29.0% | 47.1% | 42.0% | 33.0% | -92.7% | -0.6% | -11.7% | 8.3% |
| Debt to Equity | 0.00x | 0.00x | 0.00x | 0.00x | 0.03x | 0.06x | 0.03x | 0.05x | 0.07x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Jiangsu Bioperfectus Technologies Co Ltd dividends
- Dividend yield
- 9.90%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Sep 11, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 293M | 3.47 | - |
| 2024 | CNY 7.08M | 0.07 | - |
| 2023 | CNY 6.04M | 0.07 | - |
| 2022 | CNY 586M | 6.76 | 32.1% |
| 2021 | CNY 322M | 3.72 | 27.0% |
| 2020 | CNY 176M | 2.03 | 21.5% |
| 2019 | CNY 176M | 2.63 | 210.0% |
| 2018 | CNY 176M | 2.70 | 275.6% |
| 2017 | CNY 34.3M | 0.53 | 80.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.48:1 on Jul 10, 2026.
Who owns Jiangsu Bioperfectus Technologies Co Ltd
- Insiders 46.62%
- Institutions 0.95%
- Public & others 52.43%
- Shares outstanding 124M
- Free float 63.1M
Jiangsu Bioperfectus Technologies Co Ltd company profile
- Company name
- Jiangsu Bioperfectus Technologies Co Ltd
- Ticker
- 688399.SHG
- ISIN
- CNE1000055B2
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 581
- Fiscal year end
- December
- Address
- No. 837 Yaocheng Avenue, Taizhou, China, 225300
- Phone
- 86 52 3862 01616
- Website
- s-sbio.com
About Jiangsu Bioperfectus Technologies Co Ltd
Jiangsu Bioperfectus Technologies Co., Ltd., a molecular diagnostic company, engages in the research, development, production, and sale of in vitro diagnostic products in China. The company offers in vitro diagnostic reagents and supporting testing equipment, as well as in vitro testing services. It also provides HPV and cervical cancer testing services, respiratory infection detection solution, solutions for infectious diarrhea, and STI detection solution for reproductive tract infections. In addition, the company offers biological technology platforms, including nucleic acid detection platforms, NGS technology platforms, POCT technology platforms, mass spectrometry technology platforms, and automated control and detection platforms. Jiangsu Bioperfectus Technologies Co., Ltd. was founded in 2010 and is headquartered in Taizhou, China.
Jiangsu Bioperfectus Technologies Co Ltd management
5- Dr. Guoqiang WangChairman & GM · born 1970
- Ms. Yuanyuan MengFinancial Director · born 1984
- Ms. Yuanyuan HuDeputy GM, Secretary & Director · born 1986
- Mr. Guohui ZhouDeputy General Manager · born 1973
- Mr. Haidong ShenDeputy General Manager of R&D Center · born 1970